ATE236271T1 - Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung - Google Patents

Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung

Info

Publication number
ATE236271T1
ATE236271T1 AT94916604T AT94916604T ATE236271T1 AT E236271 T1 ATE236271 T1 AT E236271T1 AT 94916604 T AT94916604 T AT 94916604T AT 94916604 T AT94916604 T AT 94916604T AT E236271 T1 ATE236271 T1 AT E236271T1
Authority
AT
Austria
Prior art keywords
ndv
medicine
produce
cancer treatment
mammal
Prior art date
Application number
AT94916604T
Other languages
English (en)
Inventor
Robert M Lorence
Kirk W Reichard
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of ATE236271T1 publication Critical patent/ATE236271T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94916604T 1993-04-30 1994-04-29 Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung ATE236271T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5551993A 1993-04-30 1993-04-30
PCT/US1994/004732 WO1994025627A1 (en) 1993-04-30 1994-04-29 Methods of treating and detecting cancer using viruses

Publications (1)

Publication Number Publication Date
ATE236271T1 true ATE236271T1 (de) 2003-04-15

Family

ID=21998395

Family Applications (3)

Application Number Title Priority Date Filing Date
AT94916604T ATE236271T1 (de) 1993-04-30 1994-04-29 Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
AT02026340T ATE401092T1 (de) 1993-04-30 1994-04-29 Gereinigte zusammensetzungen von newcastle- krankheitvirus
AT04017349T ATE411809T1 (de) 1993-04-30 1994-04-29 Zusuammensetzungen zur behandlung von krebs mittels viren

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT02026340T ATE401092T1 (de) 1993-04-30 1994-04-29 Gereinigte zusammensetzungen von newcastle- krankheitvirus
AT04017349T ATE411809T1 (de) 1993-04-30 1994-04-29 Zusuammensetzungen zur behandlung von krebs mittels viren

Country Status (12)

Country Link
US (2) US7056689B1 (de)
EP (4) EP1486211B1 (de)
JP (3) JP4338781B2 (de)
AT (3) ATE236271T1 (de)
AU (1) AU699487B2 (de)
CA (1) CA2161671A1 (de)
DE (3) DE69435155D1 (de)
DK (3) DK1314431T3 (de)
ES (3) ES2196026T3 (de)
HK (1) HK1052871A1 (de)
PT (3) PT696326E (de)
WO (1) WO1994025627A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT696326E (pt) * 1993-04-30 2003-08-29 Wellstat Biologics Corp Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
NZ503664A (en) * 1997-10-09 2002-08-28 Pro Virus Inc A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
FR2788099B1 (fr) 1999-01-06 2001-02-09 Vallourec Mannesmann Oil & Gas Assemblage filete de deux tubes metalliques a couple eleve de vissage
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
NZ550861A (en) * 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
CN1250711C (zh) 2000-06-26 2006-04-12 威尔斯达特生物制剂公司 用病毒清除细胞
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
IL157504A0 (en) 2001-05-11 2004-03-28 Wellstat Biologics Corp Oncolytic virus therapy
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) * 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
EP1539230A4 (de) 2002-06-21 2007-10-31 Wellstat Biologics Corp Verabreichung von therapeutischen viren
EP1578451A4 (de) * 2002-11-05 2007-01-24 Wellstat Biologics Corp Behandlung von karzinoiden neoplasmen mit therapeutischen viren
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
KR20050115930A (ko) * 2003-03-24 2005-12-08 웰스테트 바이올로직스 코포레이션 항-암 바이러스의 탈감작화 방법
CN1902312B (zh) * 2003-11-04 2011-02-23 株式会社载体研究所 制备导入了基因的树突细胞的方法
WO2005051433A1 (en) * 2003-11-25 2005-06-09 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
CN1946421B (zh) * 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
CA2571844A1 (en) * 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing minus-strand rna virus
NZ562951A (en) 2005-07-14 2011-09-30 Wellstat Biologics Corp Cancer treatment using a Newcastle disease virus, a fluoropyrimidine and a camptothecin combination
MX2008007056A (es) 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
US20090175826A1 (en) * 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
JP5547640B2 (ja) * 2008-09-16 2014-07-16 ジェノミディア株式会社 前立腺癌の治療・予防剤
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
AU2018265258B2 (en) 2017-05-10 2023-01-05 Pharma Cinq, Llc Enveloped virus resistant to complement inactivation for the treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577525A (en) 1964-07-01 1971-05-04 Cornell Res Foundation Inc Adenovirus vaccine against canine hepatitis
NL7111160A (de) 1971-03-09 1972-09-12
ZA754725B (en) 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
JPS5173117A (en) * 1974-12-19 1976-06-24 Handai Biseibutsubyo Kenkyukai Ganryohozaino seiho
US4108983A (en) 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US4126671A (en) 1976-08-17 1978-11-21 Pitman-Moore, Inc. Method for detecting bovine leukemia viral infection
US4379839A (en) 1977-05-23 1983-04-12 The Trustees Of Columbia University In The City Of New York Method for detecting cancer
IT1117218B (it) 1979-05-18 1986-02-17 Depa Sas Procedimento per la produzione di un prodotto per la diagnosi dei tumori delle parti molli o carcinomi e prodotto ottenuto
US4282315A (en) 1979-09-13 1981-08-04 Corning Glass Works Preparation of enriched whole virus radioligand
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4465769A (en) 1981-12-11 1984-08-14 The United States Of America As Represented By The Department Of Health And Human Services Non-transformed thymidine kinaseless cell line and its use for testing tumorigenic potential of genes
JPS58116422A (ja) 1981-12-28 1983-07-11 Green Cross Corp:The 抗腫瘍剤
US4582787A (en) 1982-12-30 1986-04-15 Frankel Jack W Method of testing a patient for a predisposition to lung cancer, certain other cancers, neurofibromatosis and certain other hereditary disorders
US4571385A (en) 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
US4748109A (en) 1983-07-01 1988-05-31 Baird Phillip J Assay method and reagent to determine antibodies to papillomavirus virions
US4647773A (en) 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS60249058A (ja) 1984-05-25 1985-12-09 Eisai Co Ltd Ａｔｌウイルス抗体の測定方法および試薬
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
US5075213A (en) 1984-07-27 1991-12-24 City Of Hope Method for detection and prevention of human cytomegalovirus infection
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
FR2593828B2 (fr) 1986-01-31 1990-05-04 Pasteur Institut Sonde a papillomavirus et procede de diagnostic in-vitro d'infections a papillomavirus
US4735895A (en) 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
GB8500918D0 (en) 1985-01-15 1985-02-20 Cancer Res Inst Viral isolates
US4786590A (en) 1985-01-15 1988-11-22 California Institute Of Technology Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis
US4970071A (en) 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
EP0252940A4 (de) 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Antisense-rna zur behandlung von retroviralen krankheiten.
AU602875B2 (en) 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4861720A (en) 1986-07-03 1989-08-29 Regents Of The University Of California Oncornavirus vaccines and feline alpha-type interferon
NZ224567A (en) * 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
US4849334A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de) 1987-07-11 1989-01-19 Behringwerke Ag Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
DE68929343T2 (de) 1988-02-16 2002-09-12 Greatbatch Gen-Aid, Ltd. Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5077198A (en) 1988-04-14 1991-12-31 Eastman Kodak Company Diagnostic kit and method for rapid detection of antibodies
US5124148A (en) 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5057314A (en) 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
FR2639225B1 (fr) 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
US5169753A (en) 1989-06-05 1992-12-08 Genelabs Incorporated Method and kit for detecting human retrovirus
FR2656627B1 (fr) 1989-12-28 1992-04-17 Pasteur Institut Sonde a papillomavirus (hvpv63), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
CN1054192A (zh) * 1990-02-26 1991-09-04 张炳团 人体内诱导干扰素的制造方法
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5195539A (en) * 1992-03-23 1993-03-23 Minnesota Mining And Manufacturing Company Earplug compression device
DK0713397T3 (da) 1992-03-24 2003-03-31 United Cancer Res Inst Vaccine indeholdende levende virus
DK0931830T3 (da) 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
KR960701208A (ko) 1993-03-16 1996-02-24 엔 엔 데이비스 바이러스 단백질에 의해 면역 반응을 자극하는 방법(stimulation of immune response by viral protein)
PT696326E (pt) * 1993-04-30 2003-08-29 Wellstat Biologics Corp Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1578451A4 (de) * 2002-11-05 2007-01-24 Wellstat Biologics Corp Behandlung von karzinoiden neoplasmen mit therapeutischen viren

Also Published As

Publication number Publication date
EP1314431B1 (de) 2008-07-16
JP2009149689A (ja) 2009-07-09
DE69435155D1 (de) 2008-12-04
ES2315595T3 (es) 2009-04-01
EP1314431A2 (de) 2003-05-28
EP1486211B1 (de) 2008-10-22
EP0696326A1 (de) 1996-02-14
JP2005187484A (ja) 2005-07-14
US7056689B1 (en) 2006-06-06
WO1994025627A1 (en) 1994-11-10
AU6821394A (en) 1994-11-21
DK1314431T3 (da) 2008-11-10
EP0696326B1 (de) 2003-04-02
EP1314431A3 (de) 2003-06-18
DE69435118D1 (de) 2008-08-28
PT1486211E (pt) 2009-02-02
ATE401092T1 (de) 2008-08-15
DK0696326T3 (da) 2003-06-23
ES2310580T3 (es) 2009-01-16
CA2161671A1 (en) 1994-11-10
DE69432409T2 (de) 2003-12-24
DE69432409D1 (de) 2003-05-08
PT696326E (pt) 2003-08-29
JPH09503995A (ja) 1997-04-22
HK1052871A1 (en) 2003-10-03
EP1486211A1 (de) 2004-12-15
DK1486211T3 (da) 2009-01-19
AU699487B2 (en) 1998-12-03
EP0696326A4 (de) 1997-08-20
US7736640B2 (en) 2010-06-15
JP4338781B2 (ja) 2009-10-07
ES2196026T3 (es) 2003-12-16
DK0696326T5 (da) 2003-07-14
US20060216310A1 (en) 2006-09-28
PT1314431E (pt) 2008-10-24
ATE411809T1 (de) 2008-11-15
EP2009119A1 (de) 2008-12-31

Similar Documents

Publication Publication Date Title
DE69432409D1 (de) Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
RU94022480A (ru) Способ лечения гепатита, композиция, усиливающая ин виво инактивацию вируса гепатита с, препарат для лечения гепатита с
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
DE69433889D1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
BR0103736A (pt) Uso de uma composição que compreende pelo menos um composto metalo-orgânico e processo de tratamento das matérias queratìnicas
ES2158093T3 (es) Compuesto del 9-desoxotaxano.
ATE110265T1 (de) Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
DK0602702T3 (da) Anvendelse af tyloxapol som nanopartikelstabilisator og dispergeringsmiddel
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
EA199900620A1 (ru) Фталазиноны
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
DE68918217D1 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
BR0205473A (pt) Composição cosmética ou dermatológica de uso tópico, uso de uma composição, processo para melhorar a estabilidade de pelo menos um derivado do dibenzoilmetano e uso de um derivado de 2-hidroxibenzofenona amino-substituìdo
DE69123363D1 (de) Neue zusammensetzungen
FI961380A7 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitam iseksi
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
BR0205475A (pt) Composição cosmética ou dermatológica de uso tópico, uso de uma composição, uso de um derivado de 2-hidroxibenzofenona amino-substituìdo e processo para melhorar a estabilidade de um derivado de 1,3,5 triazina fotossensìvel em presença de um derivado de dibenzoilmetano
DE3767308D1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
ES2125309T3 (es) Derivados de tiomarinol y procedimientos para su preparacion.
DE3676640D1 (de) Prazosin-pirbuterol-mischung zur bronchendilatation.
DE58907417D1 (de) Verfahren zur Herstellung von Addukten von 1,2-Butylenoxid an Alkohole.
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
BR9106596A (pt) Processo para o tratamento ou profilaxia de uma infeccao associada com retrovirus,uso,composicao farmaceutica para o tratamento ou profilaxia de uma infeccao associada com retrovirus,e,composto
SE8303886D0 (sv) Synergetisk antihypertensiv farmaceutisk komposition
DE59304579D1 (de) Verfahren zur Herstellung von 1,3-Dialkyl-5-hydroxyoxindolen und deren Etherderivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0696326

Country of ref document: EP

REN Ceased due to non-payment of the annual fee